drugset / Trial / NCT00641082
A Double-Blind Randomized Clinical Trial Comparing the Safety and Antiviral Activity of 48-week Clevudine and Adefovir Dipivoxil in HBeAg(-) Chronic Hepatitis B With Compensated Liver Function
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A double-blind randomized, parallel, multicenter with 48 weeks of treatment period. The purpose of this study is to compare the safety and antiviral activity of 48-week Clevudine and Adefovir dipivoxil in HBeAg(-) Chronic Hepatitis B with compensated liver function.
Timeline
- Start
- 2008-02
- Primary completion
- 2012-03
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Adefovir dipivoxil | Small molecule | 10 mg | — |
| Subject | Clevudine | Small molecule | 30 mg | — |